Hemab Therapeutics Holdings, Inc. (COAG) earnings
Quarterly results of Hemab Therapeutics Holdings, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 4 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Hemab Therapeutics Holdings, Inc. reported revenue of - and a net loss of $24.2M.
Diluted earnings per share were -$0.80.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | - | - | -$24.2M | -$0.80 |
| Q1 FY2026 | - | - | -$22.7M | -$23.98 |
| Q2 FY2026 | - | - | -$12.2M | -$12.91 |
| Q1 FY2026 | - | - | -$15.3M | -$16.18 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
Get an email when COAG reports
Follow COAG and we email you its next results the day they are filed, with the numbers explained.